ECVT Ecovyst (ECVT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Chemicals & allied products · CIK 0001708035
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
125
13F, latest reported quarter
What the filings say about ECVT
Insiders, 180 days
+$137.4K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Ecovyst insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Ecovyst Inc. insiders bought a net $137.4K of stock across 116 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 73.2% of the 33,974 shares held after it.
- No other insider bought within 30 days.
- 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Humble Patti A. bought about $250.0K of ECVT on Sep 10, 2026, the largest insider purchase at the company since 2022; 125 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 15.4% of the 54,700 shares held after it.
- No other insider sold within 30 days.
- 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lorance Sarah sold about $112.6K of ECVT on Jun 2, 2026; 125 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 22, 2024.
- The trade is 19.2% of the 78,261 shares held after it.
- No other insider sold within 30 days.
- 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ward Susan F sold about $126.0K of ECVT on Nov 7, 2025, the largest insider sale at the company since 2024; 125 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 13.6% of the 57,542 shares held after it.
- 3 other insiders bought within 30 days.
- 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Whittleston Paul bought about $50.8K of ECVT on Aug 7, 2024; 3 other insiders bought within 30 days and 125 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 4, 2022.
- +1.9% median (+1.9% mean) 90-day return after 2 previous buys.
- The trade is 0.9% of the 544,609 shares held after it.
- 3 other insiders bought within 30 days.
- 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Koscinski Joseph S. bought about $30.1K of ECVT on Aug 5, 2024; 3 other insiders bought within 30 days and 125 funds added in the latest 13F quarter.116 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$137.4K over 180 days
+$250.0K over 90 days
more than 78% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
125 funds bought in last quarter
more than 77% of Pharma & Biotech
Revenue
+20.9% year over year
more than 67% of Pharma & Biotech
Margin
-9.8% net margin
more than 64% of Pharma & Biotech
Buybacks
$36.3M repurchased, FY to 2026-06-30
more than 51% of Pharma & Biotech
Short interest
6.0% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ECVT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.4%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ECVT: institutional holders (13F)
13F holdings, latest reported quarter
10,666,032 sh
$132.8M
8,211,888 sh
$102.2M
6,585,047 sh
$82.0M
6,090,922 sh
$75.8M
5,333,701 sh
$66.4M
Congress trades in ECVT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ECVT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Susan Ward
Filed 2026-07-17
$385.5K
ECVT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
BALLAST SMALL/MID CAP ETF
$4.8M position · as of 2026-06-30
2.7%
Brown Advisory Small-Cap Fundamental Value Fund
$27.1M position · as of 2026-06-30
2.2%
Invesco Dorsey Wright Basic Materials Momentum ETF
$1.1M position · as of 2026-07-31
1.5%
Easterly Snow Long/Short Opportunity Fund
$1.7M position · as of 2026-05-31
1.5%
Brown Advisory Sustainable Small-Cap Core Fund
$1.5M position · as of 2026-06-30
1.3%
Loomis Sayles Small Cap Value Fund
$2.7M position · as of 2026-06-30
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $137.4K bought by insiders over 180 days, 125 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ECVT financials
Revenue growth
+20.9%
XBRL, annual
Net margin
-9.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM ECVT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $691.1M |
| FY Dec 2022 | $820.2M |
| FY Dec 2021 | $611.2M |
| Jun 2026 | $250.0M |
| Mar 2026 | $215.0M |
| Dec 2025 | $199.4M |
| Sep 2025 | $204.9M |
| Jun 2025 | $200.1M |
| Mar 2025 | $162.2M |
| Dec 2024 | $148.9M |
| Sep 2024 | $179.2M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM ECVT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +10.3% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +3.1% |
| Mar 2026 | +2.0% |
| Dec 2025 | +2.9% |
| Sep 2025 | -38.7% |
| Jun 2025 | +3.0% |
| Mar 2025 | -2.2% |
| Dec 2024 | -20.4% |
| Sep 2024 | +8.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$72.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ECVT
| FY Dec 2025 | $69.9M |
| FY Dec 2024 | $94.3M |
| FY Dec 2023 | $78.6M |
| FY Dec 2022 | $127.7M |
| FY Dec 2021 | $69.9M |
| Jun 2026 | $3.7M |
| Mar 2026 | $2.8M |
| Dec 2025 | $22.9M |
| Sep 2025 | $42.8M |
| Jun 2025 | $11.0M |
| Mar 2025 | -$6.8M |
| Dec 2024 | $30.9M |
| Sep 2024 | $53.6M |
At each fiscal year end
Single quarter
Debt to equity
0.84x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity ECVT
| FY Dec 2025 | 0.65x |
| FY Dec 2024 | 1.23x |
| FY Dec 2023 | 1.23x |
| FY Dec 2022 | 1.24x |
| FY Dec 2021 | 1.19x |
| Jun 2026 | 0.84x |
| Mar 2026 | 0.68x |
| Dec 2025 | 0.65x |
| Sep 2025 | 1.41x |
| Jun 2025 | 1.24x |
| Mar 2025 | 1.23x |
| Dec 2024 | 1.23x |
| Sep 2024 | 1.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.30x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt ECVT
| FY Dec 2025 | 0.36x |
| FY Dec 2024 | 0.17x |
| FY Dec 2023 | 0.16x |
| FY Dec 2022 | 0.21x |
| FY Dec 2021 | 0.15x |
| Jun 2026 | 0.30x |
| Mar 2026 | 0.37x |
| Dec 2025 | 0.36x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.14x |
| Dec 2024 | 0.17x |
| Sep 2024 | 0.20x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-9.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ECVT
| FY Dec 2025 | -10.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +10.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -9.6% |
| Mar 2026 | -9.9% |
| Dec 2025 | -10.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +7.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-3.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ECVT
| FY Dec 2025 | -4.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +3.8% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -3.8% |
| Mar 2026 | -4.2% |
| Dec 2025 | -4.6% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +2.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital ECVT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +5.1% |
| FY Dec 2022 | +5.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ECVT
| FY Dec 2025 | +4.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | +5.9% |
| FY Dec 2021 | +2.3% |
| Jun 2026 | +5.6% |
| Mar 2026 | +5.6% |
| Dec 2025 | +4.6% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +4.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ECVT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 16.02x |
| FY Dec 2022 | 15.82x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 14.89x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.5B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value ECVT
| FY Dec 2025 | $1.3B |
| FY Dec 2024 | $1.6B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $1.9B |
| FY Dec 2021 | $2.1B |
| Jun 2026 | $1.8B |
| Mar 2026 | $1.7B |
| Dec 2025 | $1.3B |
| Sep 2025 | $1.8B |
| Jun 2025 | $1.8B |
| Mar 2025 | $1.5B |
| Dec 2024 | $1.6B |
| Sep 2024 | $1.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield ECVT
| FY Dec 2025 | +6.3% |
| FY Dec 2024 | +10.6% |
| FY Dec 2023 | +6.9% |
| FY Dec 2022 | +11.1% |
| FY Dec 2021 | +5.0% |
| Jun 2026 | +5.3% |
| Mar 2026 | +5.6% |
| Dec 2025 | +6.3% |
| Sep 2025 | +7.8% |
| Jun 2025 | +9.2% |
| Mar 2025 | +9.4% |
| Dec 2024 | +10.6% |
| Sep 2024 | +15.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ECVT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 1.79x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $723.5M | $704.5M | $691.1M | $820.2M |
| Gross profit | $158.1M | $163.4M | $166.4M | $224.6M |
| Operating income | $64.9M | $85.1M | $89.6M | $104.4M |
| Net income | -$71.1M | -$6.7M | $71.2M | $69.8M |
| EPS (diluted) | -0.61 | -0.06 | 0.60 | 0.55 |
| Operating cash flow | $140.3M | $149.9M | $137.6M | $186.6M |
| Cash | $197.2M | $131.4M | $88.4M | $110.9M |
| Long-term debt | $392.6M | $852.1M | $858.9M | $865.9M |
| Buybacks | $46.9M | $5.0M | $78.7M | $136.7M |
| Dividends paid | n/a | n/a | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
ECVT Stock Sonar score 6/7 axes
Find similar shapesCompareECVT ranks highest on profitability (81st percentile) and institutional and government (77th), and lowest on risk and compliance (47th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ECVT filings, in plain words
Are Ecovyst insiders buying or selling ECVT?
In the 180 days to 2026-10-27, Ecovyst insiders were net buyers, a net $137.4K: $250.0K of purchases and $112.6K of sales reported on Form 4, by 1 buyer and 1 seller.
Read the full summary
In the 180 days to 2026-10-27, Ecovyst insiders were net buyers of ECVT, a net $137.4K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
